Selank Safety Questions: What Studies Report

What This Page Covers

People searching for Selank safety information usually want three things: a list of reported adverse events, a statement about specific organs or populations, and an honest account of what has never been studied. This page summarises only the published papers listed in the References section, describing each by model, endpoint and what the authors reported. It does not extrapolate from animal findings to people, and it does not describe protocols, quantities or regimens. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

One point matters more than any other for reading this literature: the Selank studies available in English-language indexing were designed as pharmacology experiments, not as toxicology or safety trials. Researchers measured behaviour, gene expression, cytokines and tissue morphology. Adverse events were generally not the outcome being tracked, so the absence of a reported harm in a given paper usually means the question was not asked.

Does Selank Cause Hair Loss: What Studies Report

None of the verified studies summarised on this page reported hair loss, alopecia, thinning, coat changes, or any dermatological outcome. The published work covered anxiety-like behaviour in rats under chronic mild stress (2017), liver morphology under chronic foot-shock stress (2019), and cytokine levels under "social" stress (2021) — none of which included skin, hair follicle or coat scoring as a measured endpoint.

That distinction is important. A study that never photographed, weighed or histologically examined skin cannot report an effect on hair, in either direction. So the accurate statement is not "studies found Selank does not cause hair loss" but rather "no study in this set measured hair or skin outcomes at all." Readers encountering anecdotal reports online should understand that no published, peer-reviewed animal or human dataset in the group reviewed here speaks to that question. Hormonal endpoints such as androgens, thyroid hormones or cortisol-driven telogen effluvium — the mechanisms most often invoked in hair-loss discussions — were likewise not endpoints in these papers.

Liver and Hepatocyte Findings: What Studies Report

Two Bulletin of Experimental Biology and Medicine papers examined the liver directly, which makes them the closest thing in this set to organ-level safety data. A 2019 study assessed morphological parameters of rat liver during chronic foot-shock stress and reported on how Selank administration related to those stress-associated tissue changes (2019). A separate 2017 study evaluated the functional state of rat hepatocytes under restraint stress conditions (2017).

Both were framed as investigations of whether the peptide modified stress-induced hepatic changes, not as hepatotoxicity screens in healthy untreated animals. Researchers in the hepatocyte study looked at functional parameters of liver cells; researchers in the morphology study looked at tissue structure. Neither paper is equivalent to a human liver function panel, and neither enrolled people. Anyone wanting to know whether Selank affects human liver enzymes will not find that answer in this literature.

Immune and Cytokine Findings: What Studies Report

Selank is a synthetic analogue of tuftsin, an endogenous immunomodulatory fragment, so immune endpoints are mechanistically relevant. A 2021 paper examined the influence of Selank on cytokine levels under conditions of "social" stress (2021). The study framed cytokines as a readout of the stress response rather than as a safety signal, and reported on how the peptide related to those inflammatory mediators in the stress model used.

For safety reading, the relevant point is that immune signalling is a plausible site of action and was measured in at least one published model. Whether modulation of cytokines is beneficial, neutral or undesirable depends entirely on context, and the paper did not characterise immunosuppression, infection risk or autoimmune outcomes in humans.

Central Nervous System and Behaviour: What Studies Report

The largest share of the Selank literature is behavioural and neurochemical. A 2003 paper reported an optimising action of the synthetic peptide on a conditioned active avoidance reflex in rats (2003). A 2008 Russian-language study examined effects on genetically based and situation-provoked depression-like signs in WAG/Rij and Wistar rats and in BALB/c mice (2008), and a 2019 study reported that the peptide protected against ethanol-induced memory impairment in rats while examining BDNF content in the hippocampus and prefrontal cortex (2019).

Other work extended to disease models. A 2017 paper examined how semax and Selank affected the behaviour of rats with 6-OHDA-induced Parkinson's-disease-like parkinsonism (2017), and a 2022 study reported that the tuftsin analogue attenuated aversive signs of morphine withdrawal in rats (2022). A 2020 paper applied a functional connectomic approach to characterising the effects of Selank and Semax on brain networks (2020).

None of these reports were designed to catalogue neurological adverse events such as seizures, sedation scoring or withdrawal on discontinuation of the peptide itself. Notably, the morphine-withdrawal study examined withdrawal from an opioid, not dependence on or withdrawal from Selank (2022) — a distinction that is frequently blurred in secondary summaries.

Interaction Questions and Benzodiazepines: What Studies Report

Interaction data are sparse but not absent. A 2017 Behavioural Neurology study examined whether the peptide enhanced the effect of diazepam in reducing anxiety-like behaviour in rats housed under unpredictable chronic mild stress (2017). The study reported an enhancement of the benzodiazepine's anxiety-reducing effect in that model.

An enhancement finding is pharmacologically informative and, from a safety-reading perspective, is the kind of result that raises interaction questions rather than settling them. The experiment was conducted in rats, used a single benzodiazepine, and did not evaluate sedation depth, respiratory endpoints or cognitive impairment in humans taking prescribed anxiolytics. Mechanistic support for GABAergic involvement comes from cell work: a 2017 Frontiers in Pharmacology study reported that GABA, Selank and olanzapine affected the expression of genes involved in GABAergic neurotransmission in IMR-32 cells (2017). That was an in vitro neuroblastoma cell line, not a person.

Study-by-Study Overview: What Studies Report

Human Data and Special Populations: What Studies Report

Within the papers reviewed here, there is no controlled human trial reporting adverse events, no pregnancy or lactation data, no paediatric data, no data in older adults, and no data in people with kidney or liver impairment. The 2018 review in Protein and Peptide Letters summarised molecular aspects of the heptapeptide's biological activity as a peptide-based anxiolytic (2018); it is a mechanistic review rather than a source of human tolerability statistics.

That gap has practical consequences for how claims should be read. Statements circulating online about "no reported side effects" are not supported by a formal human safety dataset in this set of papers — they reflect the fact that side effects were largely not measured and not published in indexed English-language sources. Equally, claims of specific harms such as hair loss are not supported here either. The defensible position is that the question remains open.

Limitations Readers Should Weigh

• Species and route. Nearly all findings came from rats and mice, plus one human cell line (2017). Rodent results do not translate automatically to human physiology.
• Stress models dominate. Liver, cytokine and behaviour findings were generated in stressed animals (2019), which complicates separating peptide effects from stress-response effects.
• Small, single-centre studies. Much of the work appeared in a small number of journals, with limited independent replication.
• Endpoint selection. Efficacy endpoints predominate; systematic adverse-event collection is largely absent.
• Regulatory status. Selank is not an approved medicine in the United States; materials sold as research chemicals are labelled research-use-only and are not manufactured or tested to pharmaceutical standards.

How This Page Should Be Used

This summary exists so that readers can see what was actually measured, in which species, and what the authors reported — nothing more. It makes no recommendation about use, quantity, frequency or combination with any other substance, and it should not be treated as a substitute for evaluation by a qualified clinician who knows an individual's history and medications.

References

• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (Behavioural Neurology, 2017)
• Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress (Bulletin of Experimental Biology and Medicine, 2019)
• The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress (Current Reviews in Clinical and Experimental Pharmacology, 2021)
• Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats (Bulletin of Experimental Biology and Medicine, 2022)
• Peptides Semax and Selank Affect the Behavior of Rats with 6-OHDA Induced PD-like Parkinsonism (Doklady Biological Sciences, 2017)
• The Optimizing Action of the Synthetic Peptide Selank on a Conditioned Active Avoidance Reflex in Rats (Neuroscience and Behavioral Physiology, 2003)
• Effects of Heptapeptide Selank on Genetically-Based and Situation-Provoked Symptoms of Depression in Behavior in WAG/Rij and Wistar Rats, and in BALB/c Mice (Zhurnal Vysshei Nervnoi Deiatelnosti, 2008)
• Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity (Protein and Peptide Letters, 2018)
• Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress (Bulletin of Experimental Biology and Medicine, 2017)
• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells (Frontiers in Pharmacology, 2017)
• Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats (Bulletin of Experimental Biology and Medicine, 2019)